

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number  
**WO 03/051384 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 38/00**,  
39/00, 45/00

(21) International Application Number: PCT/US02/40309

(22) International Filing Date:  
17 December 2002 (17.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/341,783 17 December 2001 (17.12.2001) US

(71) Applicant: LUNN, Paul, G. [US/US]; Zymogenetics,  
Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).

(72) Inventors: CHANDRASEKHER, Yasmi, A.; 5912 83rd  
PL SE, Mercer Island, WA 98040 (US). MCKERNAN,  
Patricia, A.; 18459 NE 196th Place, Woodinville, WA  
98072 (US).

(74) Agent: LUNN, Paul, G.; ZymoGenetics, Inc., 1201 East-  
lake Ave E, Seattle, WA 98102 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).


**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*



**WO 03/051384 A1**



(54) Title: METHOD FOR TREATING CERVICAL CANCER

(57) Abstract: Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus . IL-20 can be ad-  
ministered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.

## METHOD FOR TREATING CERVICAL CANCER

5

### BACKGROUND OF THE INVENTION

According to the American Cancer Society, 12,800 new cases of invasive cervical cancer would be diagnosed in the United States in 1999. During the same year,  
10 4800 patients were expected to die of the disease. This represents approximately 1.8% of all cancer deaths in women and 18% of gynecological cancer deaths. However, for women aged 20 to 39 years of age, cervical cancer is the second leading cause of cancer deaths. Molecular and epidemiologic studies have demonstrated a strong relationship between human papillomavirus (HPV), cervical intraepithelial neoplasia, (CIN), and  
15 invasive carcinoma of the cervix. Thus, there is a need to develop new therapeutic entities for the treatment of human papillomavirus infection, cervical intraepithelial neoplasia and carcinoma of the cervix.

### DESCRIPTION OF THE INVENTION

20

The present invention fills this need by administering interleukin-20 (IL-20) to a mammalian having cervical cancer. IL-20 can also be used to treat a human papillomavirus infection. The present invention also provides a method for inhibiting the growth of cervical cancer cells by bringing IL-20 into contact with said cancerous  
25 cervical cells. Interleukin-20 (formally called Zcyto10) can be produced according to the method described in International Patent Application No. PCT/US98/25228 filed on November 25 1998. The human IL-20 polypeptide is comprised of a sequence of 176 amino acids with the initial Met as shown in SEQ ID NO:1 and SEQ ID NO:2. It is believed that amino residues 1-24 are signal sequence, and the mature IL-20  
30 polypeptide is represented by the amino acid sequence comprised of residues 25, a leucine, through amino acid residue 176, a glutamic acid residue, also defined by SEQ ID NO:12. Another embodiment of the present invention is defined by the sequences of SEQ ID NO: 3 and SEQ ID NO: 4. The polypeptide of SEQ ID NO: 4 is comprised of

151 amino acid residues wherein amino acids 1-24 comprise a signal sequence and the mature sequence is comprised of amino acid residues 25, a leucine, through amino acid 151 a glutamic acid, also defined by SEQ ID NO:13. Another active variant is comprised of amino acid residues 33, a cysteine, through amino acid residue 176 of SEQ ID NO:2. This variant is also defined by SEQ ID NO:26.

Mouse IL-20 is also a polypeptide comprised of 176 amino acid residues as defined by SEQ ID NOs: 18 and 19. Mouse IL-20 has a signal sequence extending from amino acid residue 1, a methionine, extending to and including amino acid residue 24, a glycine of SEQ ID NO:19. Thus, the mature mouse IL-20 extends from amino acid residue 25, a leucine, to and including amino acid residue 176 a leucine of SEQ ID NO:19, also defined by SEQ ID NO:20. Another active variant is believed to extend from amino acid 33, a cysteine, through amino acid 176, of SEQ ID NO:19. This variant is also defined by SEQ ID NO:25.

A variant of mouse IL-20 is defined by SEQ ID NOs: 33 and 34. This variant is 154 amino acid residues in length and has a signal sequence extending from amino acid residue 1, a methionine, to and including amino acid residue 24, a glycine, of SEQ ID NO:34. Thus, the mature sequence extends from amino acid residue 25, a leucine, to and including amino acid residue 154, a leucine, of SEQ ID NO:34. The mature sequence is also defined by SEQ ID NO:35.

### **Pathology of Cervical Cancer**

Cervical dysplasia cells and cervical intraepithelial neoplasia (CIN) cells develop into invasive cervical cancer over a number of years. CIN grades I, II and III correspond to mild, moderate, and severe cervical dysplasia. CIN III, which includes severe dysplasia and carcinoma *in situ*, is unlikely to regress spontaneously and, if untreated, may eventually penetrate the basement membrane, becoming invasive carcinoma. Squamous cell carcinoma accounts for 80 to 85% of all cervical cancers; adenocarcinomas account for most of the rest. Invasive cervical cancer usually spreads by direct extension into surrounding tissues and the vagina or via the lymphatics to the pelvic and para-aortic lymph nodes drained by the cervix. Hematologic spread is possible.

### **Symptoms, Signs and Diagnosis of Cervical Cancer**

CIN is usually asymptomatic and discovered because of an abnormal Pap smear. Patients with early-stage cervical cancer usually present with irregular vaginal bleeding, which is most often postcoital, but intermenstrual bleeding or menometrorrhagia may occur. Patients with larger cervical cancers or advanced-stage disease may present with foul-smelling vaginal discharge, abnormal vaginal bleeding, or pelvic pain. Obstructive uropathy, back pain, and leg swelling are manifestations of late-stage disease. Suspicious lesions, generally first detected by a Pap smear are biopsied. If clinical disease is invasive, staging is performed on the basis of the physical examination, with a metastatic survey including cystoscopy, sigmoidoscopy, IV pyelography, chest x-ray, and skeletal x-rays.

### **Treatment of Cervical Cancer with IL-20**

Cervical cancer can be treated by administration of IL-20 to a female mammal, particularly a human female, afflicted with the disease. IL-20 can be administered intralesionally, or intramuscularly for localized disease. For metastatic disease, IL-20 can also be administered by intraperitoneal administration including intravenous administration. IL-20 can be administered alone or in conjunction with standard therapies such as surgery, radiation or other chemotherapeutic agents such as bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.

### **Use of Interleukin-20 to Treat Cells Infected with the Human Papillomavirus/Genital Warts**

Cells infected with the human papillomavirus (HPV) can be treated with IL-20 to inhibit the proliferation of the virus. Anogenital warts caused by HPV type 6, 11, 16, 18, 31, 33 and 35 are transmitted sexually and have an incubation period of 1 to 6 months. Endocervical wart infections caused by type 16 or 18 have been implicated as a cause of cervical intraepithelial neoplasia and cervical cancer. HPV types 16 and 18 generally do not cause external genital warts, which are usually caused by types 6 and 11.

### Symptoms, Signs and Diagnosis

Genital warts usually appear as soft, moist, minute pink or gray polyps that enlarge, may become pedunculated, and are usually found in clusters. The surfaces resemble the surface of cauliflower. In men they occur most commonly on warm, moist surfaces in the subpreputial area, on the coronal sulcus, within the urethral meatus, and on the penile shaft. In women, the vulva, the vaginal wall, the cervix, and the perineum may become involved. They are particularly common in the perianal region and rectum in homosexual men. Growth rates vary, but pregnancy, immunosuppression, or maceration of the skin may accelerate both the growth of individual lesions and their spread. Genital warts usually can be identified by their appearance but must be differentiated from the flat-topped condyloma lata of secondary syphilis. Biopsies of atypical or persistent warts may be necessary to exclude carcinoma.

IL-20 can be administered directly into lesions containing cells infected with HPV alone or with standard therapies such as interferon alpha or interferon beta both of which are commercially available. Interferon alpha is available from Schering Corporation of Kenilworth, New Jersey and is called INTRON A®. Interferon beta is produced by Biogen of Cambridge, MA and is called AVONEX ®. IL-20 can also be administered with other standard therapies for treating HPV including antimetotics such as podophyllotoxin, podophyllin, or 5-fluorouracil; caustics such as trichloroacetic acid; or interferon inducers such as imiquimod.

The quantities of IL-20 for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medications administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful for *in vivo* administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Methods for administration include, intravenous, peritoneal, intramuscular, or intralesional. Pharmaceutically acceptable carriers will include water, saline, buffers to name just a few. Dosage ranges would ordinarily be expected from 1µg to 1000µg per kilogram of body weight per day. However, the doses may be higher or lower as can be determined by a medical doctor with ordinary skill in the art. Excipients and stabilizers can possibly be added. These include glycine, histidine, glutamate, aspartate, sugars, sucrose, trehalose, galactose sorbitol, arginine, D-and/or L-amino acids, sugar alcohols, lactose, maltose, threonine, lysine, methionine, isoleucine, a surface active agent such as TWEEN 80, TWEEN 20,

polyethylene glycol (PEG) (particularly those PEGs having molecular weights between 1000 and 35000 Da), cetyl alcohol, polyvinylpyrrolidone, polyvinyl alcohol, lanolin alcohol and sorbitan. A reducing agent may be included, such as cysteine, N-acetylcysteine, and thioglycerol. For a complete discussion of drug formulations and dosage ranges see *Remington's Pharmaceutical Sciences*, 18<sup>th</sup> Ed., (Mack Publishing Co., Easton, Penn., 1996), and *Goodman and Gilman's: The Pharmacological Bases of Therapeutics*, 9<sup>th</sup> Ed. (Pergamon Press 1996).

IL-20 can also be administered in conjunction with other treatments for cervical cancer such as radiation and chemotherapy. Examples of chemotherapeutic agents include bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.

### Example

We tested IL-20 in a HeLa299 cytotoxicity assay to measure the ability of IL-20 to prevent cells from growing during normal growth conditions. We used MTT reagent (Promega, Madison, USA) as our detection and readout for this cell inhibition assay. Procedure of a cytotoxicity assay:

Day 1- Plate cells out in complete growth media (with serum) at 5000cells/well in a 96well format and let them incubate overnight at 37degrees and 5% CO2.

Day 2- Dump off media and add a dose response of appropriate ligands in complete growth media (IL-20, zmda1, and MDA7 at 10, 100, and 1000 ng/ml.), along with a positive control retinoic acid (100uM) in complete growth media, while leaving some wells in complete growth media as controls of how the cells normally grow under normal conditions. Put the cells in incubator and let the assay go for 72hrs.

Day 5- Add 15ul/well of MTT reagent, let cells inc. for 4hrs., then add 100ul of stop solution, let cells inc. for an additional 1hr., then read the plate on a multilabel counter (Victor2, PerkinElmer Life Sciences Inc., Boston). The MTT protocol will give you two readings, one at a 650 wavelength (background) and one at a 572 wavelength. Subtract

the 650 reading from the 572 reading to get your actual output. These numbers are averaged and converted to a % inhibition value.

**Results:**

- 5 -Retnoic Acid gave a 53% inhibition of growth (positive control)
- IL-20 gave a maximal 20% inhibition of growth

## WHAT IS CLAIMED IS:

1. A method for inhibiting the growth and or proliferation of cervical cancer cells comprising bringing Interleukin-20 (IL-20) into contact with the cervical cancer cells.
2. The method of claim 1 wherein the cervical cancer cells are treated with radiation in conjunction with IL-20.
3. The method of claim 1 wherein the cervical cancer cells are treated with one or more additional chemotherapeutic agents in conjunction with IL-20.
4. The method of claim 3 wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.
5. A method for treating a female mammal afflicted with cervical cancer comprising administering to said female mammal IL-20.
6. The method of claim 5 wherein the IL-20 is administered in conjunction with radiation.
7. The method of claim 5 wherein the IL-20 is administered in conjunction with a chemotherapeutic agent.
8. The method of claim 7 wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.



9. A method for inhibiting the proliferation or growth of human papillomavirus (HPV) comprising bringing IL-20 into contact with cells infected with HPV.
10. The method of claim 9 wherein the IL-20 is injected into a genital wart infected with HPV.
11. The method of claim 9 wherein the IL-20 is administered in conjunction with the consisting of interferon alpha, interferon beta, podophyllotoxin, podophyllin and 5-fluorouracil, trichloroacetic acid, and imiquimod.
12. The method of claim 9 wherein the IL-20 is administered in conjunction with electrocauterization, laser, cryotherapy, or surgical excision of the cells infected with HPV.
13. A method for treating an individual infected with HPV comprising administering to said individual a therapeutically effective amount of IL-20.
14. The method of claim 13 wherein said individual has genital warts or lesions infected with HPV and the IL20 is injected into the lesions or genital warts infected.
15. The method of claim 14 wherein said the IL-20 is injected into said warts in conjunction with electrocauterization, laser, cryotherapy, or surgical excision of the genital warts or lesions infected with HPV.
16. The method of claim 14 wherein the IL-20 is administered in conjunction with the consisting of interferon alpha, interferon beta, podophyllotoxin, podophyllin and 5-fluorouracil, trichloroacetic acid, and imiquimod.
17. The use of IL-20 for the production of a medicament for the treatment of cervical cancer.

18. The use of IL-20 for the production of a medicament for the treatment of human papilloma virus infection.

## SEQUENCE LISTING

&lt;110&gt; ZymoGenetics, Inc.

&lt;120&gt; METHOD FOR TREATING CERVICAL CANCER

&lt;130&gt; 01-44PC

&lt;150&gt; 60/341,783

&lt;151&gt; 2001-12-17

&lt;160&gt; 43

&lt;170&gt; FastSEQ for Windows Version 3.0

&lt;210&gt; 1

&lt;211&gt; 926

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (45)...(572)

&lt;400&gt; 1

ctttgaattc ctagctcctg tggctctccag atttcaggcc taag atg aaa gcc tct	56
Met Lys Ala Ser	
1	
agt ctt gcc ttc agc ctt ctc tct gct gcg ttt tat ctc cta tgg act	104
Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr Leu Leu Trp Thr	
5 10 15 20	
cct tcc act gga ctg aag aca ctc aat ttg gga agc tgt gtg atc gcc	152
Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala	
25 30 35	
aca aac ctt cag gaa ata cga aat gga ttt tct gac ata cgg ggc agt	200
Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg Gly Ser	
40 45 50	
gtg caa gcc aaa gat gga aac att gac atc aga atc tta agg agg act	248
Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg Arg Thr	
55 60 65	
gag tct ttg caa gac aca aag cct gcg aat cga tgc tgc ctc ctg cgc	296
Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu Leu Arg	
70 75 80	
cat ttg cta aga ctc tat ctg gac agg gta ttt aaa aac tac cag acc	344
His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr	
85 90 95 100	

```

cct gac cat tat act ctc cgg aag atc agc agc ctc gcc aat tcc ttt      392
Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe
                105                      110                      115

ctt acc atc aag aag gac ctc cgg ctc tgt cat gcc cac atg aca tgc      440
Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys His Ala His Met Thr Cys
                120                      125                      130

cat tgt ggg gag gaa gca atg aag aaa tac agc cag att ctg agt cac      488
His Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser Gln Ile Leu Ser His
                135                      140                      145

ttt gaa aag ctg gaa cct cag gca gca gtt gtg aag gct ttg ggg gaa      536
Phe Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu
                150                      155                      160

cta gac att ctt ctg caa tgg atg gag gag aca gaa taggaggaaa      582
Leu Asp Ile Leu Leu Gln Trp Met Glu Glu Thr Glu
                165                      170                      175

gtgatgctgc tgctaagaat attcgaggtc aagagctcca gtcttcaata cctgcagagg      642
aggcatgacc ccaaaccacc atctctttac tgtactagtc ttgtgctggt cacagtgtat      702
cttatattatg cattacttgc ttccttgcac gattgtcttt atgcatcccc aatcttaatt      762
gagaccatac ttgtataaga tttttgtaat atctttctgc tattggatat atttattagt      822
taatataattt atttattttt tgctattaat gtatttaatt ttttacttgg gcatgaaact      882
ttaaaaaaaaa ttcacaagat tatatttata acctgactag agca                      926

```

<210> 2  
 <211> 176  
 <212> PRT  
 <213> Homo sapiens

```

<400> 2
Met Lys Ala Ser Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr
 1          5          10          15
Leu Leu Trp Thr Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser
 20          25          30
Cys Val Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp
 35          40          45
Ile Arg Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile
 50          55          60
Leu Arg Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys
 65          70          75          80
Cys Leu Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys
 85          90          95
Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu
100          105          110
Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys His Ala
115          120          125
His Met Thr Cys His Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser Gln
130          135          140
Ile Leu Ser His Phe Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys
145          150          155          160
Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met Glu Glu Thr Glu
165          170          175

```

<210> 3

```
<220>
<221> CDS
<222> (45) ... (497)
```

ctttgaattc ctagctcctg tggctctccag atttcaggcc taag atg aaa gcc tct 56  
Met Lys Ala Ser  
1

agt ctt gcc ttc agc ctt ctc tct gct gcg ttt tat ctc cta tgg act 104  
Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr Leu Leu Trp Thr  
5 10 15 20

cct tcc act gga ctg aag aca ctc aat ttg gga agc tgt gtg atc gcc 152  
Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala  
25 30 35

aca aac ctt cag gaa ata cga aat gga ttt tct gac ata cgg ggc agt 200  
Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg Gly Ser  
40 45 50

gtg caa gcc aaa gat gga aac att gac atc aga atc tta agg agg act 248  
Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg Arg Thr  
55 60 65

gag tct ttg caa gac aca aag cct gcg aat cga tgc tgc ctc ctg cgc 296  
Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu Leu Arg  
70 75 80

cat ttg cta aga ctc tat ctg gac agg gta ttt aaa aac tac cag acc 344  
His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr  
85 90 95 100

cct gac cat tat act ctc cgg aag atc agc agc ctc gcc aat tcc ttt 392  
Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe  
105 110 115

ctt acc atc aag aag gac ctc cgg ctc tgt ctg gaa cct cag gca gca 440  
 Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys Leu Glu Pro Gln Ala Ala  
 120 125 130

gtt gtg aag gct ttg ggg gaa cta gac att ctt ctg caa tgg atg gag 488  
Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met Glu  
135 140 145

gag aca gaa taggaggaaa gtgatgctgc tgctaagaat attcgaggtc 537  
Glu Thr Glu  
150

aagagctcca	gtcttcaata	cctgcagagg	aggcatgacc	ccaaccacc	atctctttac	597
tgtactagtc	ttgtgctggt	cacagtgtat	cttatttatg	cattacttgc	ttccttgcac	657
gattgtcttt	atgcatcccc	aatcttaatt	gagaccatac	ttgtataaga	tttttgaat	717
atctttctgc	tattggatat	atttattagt	taatataatt	atttattttt	tgctattaat	777

gtattttaatt tttttac

793

<210> 4  
 <211> 151  
 <212> PRT  
 <213> Homo sapiens

<400> 4  
 Met Lys Ala Ser Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr  
 1 5 10 15  
 Leu Leu Trp Thr Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser  
 20 25 30  
 Cys Val Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp  
 35 40 45  
 Ile Arg Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile  
 50 55 60  
 Leu Arg Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys  
 65 70 75 80  
 Cys Leu Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys  
 85 90 95  
 Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu  
 100 105 110  
 Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys Leu Glu  
 115 120 125  
 Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu  
 130 135 140  
 Gln Trp Met Glu Glu Thr Glu  
 145 150

<210> 5  
 <211> 253  
 <212> DNA  
 <213> Homo sapiens

<400> 5  
 ctttgaattc ctagctcctg tggctctccag atttcaggcc taagatgaaa gcctctagtc 60  
 ttgccttcag ccttctctct gctgcgtttt atctcctatg gactccttc actggactga 120  
 agacactcaa tttgggaagc tgtgtgatcg ccacaaacct tcaggaaata cgaaatggat 180  
 tttctgagat acggggcagt gtgcaagcca aagatggaaa cattgacatc agaatcttaa 240  
 ggaggactga gtc 253

<210> 6  
 <211> 24  
 <212> DNA  
 <213> Homo sapiens

<400> 6  
 attcctagct cctgtggtct ccag 24

<210> 7  
 <211> 25  
 <212> DNA  
 <213> Homo sapiens

<400> 7  
 ctctgctgcg ttttatctcc tatgg 25

<210> 8  
 <211> 22  
 <212> DNA  
 <213> Homo sapiens

<400> 8  
 tcccaaattg agtgtcttca gt 22

<210> 9  
 <211> 45  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 cacagcttcc caaattgagt gtcttcagtc cagtggagg agtcc 45

<210> 10  
 <211> 747  
 <212> DNA  
 <213> Homo sapiens

<400> 10  
 ttttctgaca tacggggcag tgtgcaagcc aaagatggaa acattgacat cagaatctta 60  
 aggaggactg agtcttttga agacacaaag cctgcgaatc gatgctgcct cctgcgccat 120  
 ttgctaagac tctatctgga caggggtattt aaaaactacc agaccctga ccattatact 180  
 ctccggaaga tcagcagcct cgccaattcc tttcttacca tcaagaagga cctccggctc 240  
 tgtcatgccc acatgacatg ccatttgtggg gaggaagcaa tgaagaaata cagccagatt 300  
 ctgagtcact ttgaaaagct ggaacctcag gcagcagttg tgaaggcttt gggggaacta 360  
 gacattcttc tgcaatggat ggaggagaca gaataggagg aaagtgatgc tgctgctaag 420  
 aatattcgag gtcaagagct ccagtcttca atacctgcag aggaggcatg accccaaacc 480  
 accatctctt tactgtacta gtcttgtgct ggtcacagtg tatcttattt atgcattact 540  
 tgcttccttg catgattgtc tttatgcac cccaatctta attgagacca tacttgata 600  
 agatttttgt aatatcttct tgctattgga tatatttatt agttaatata tttatttatt 660  
 ttttgcattt aatgtattta attttttact tgggcattgaa actttaaaaa aaattcacia 720  
 gattatattt ataacctgac tagagca 747

<210> 11  
 <211> 614  
 <212> DNA  
 <213> Homo sapiens

<400> 11  
 ttttctgaca tacggggcag tgtgcaagcc aaagatggaa acattgacat cagaatctta 60  
 aggaggactg agtcttttga agacacaaag cctgcgaatc gatgctgcct cctgcgccat 120  
 ttgctaagac tctatctgga caggggtattt aaaaactacc agaccctga ccattatact 180  
 ctccggaaga tcagcagcct cgccaattcc tttcttacca tcaagaagga cctccggctc 240  
 tgtctggaac ctacggcagc agttgtgaa gctttggggg aactagacat tcttctgcaa 300  
 tggatggagg agacagaata ggaggaaagt gatgctgctg ctaagaatat tcgagggtcaa 360  
 gagctccagt cttcaatacc tgcagaggag gcatgacccc aaaccacat ctctttactg 420  
 tactagtctt gtgctggtca cagtgtatct tatttatgca ttacttgctt ccttgcatga 480  
 ttgtctttat gcatcccaa tcttaattga gaccatactt gtataagatt tttgtaatat 540  
 ctttctgcta ttggatatat ttattagtta atatatattt ttattttttg ctattaatgt 600  
 atttaatttt ttac 614

<210> 12  
 <211> 152  
 <212> PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

```

Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala Thr Asn Leu Gln
 1           5           10           15
Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg Gly Ser Val Gln Ala Lys
          20           25           30
Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg Arg Thr Glu Ser Leu Gln
          35           40           45
Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu Leu Arg His Leu Leu Arg
          50           55           60
Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr
65           70           75           80
Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr Ile Lys
          85           90           95
Lys Asp Leu Arg Leu Cys His Ala His Met Thr Cys His Cys Gly Glu
          100          105          110
Glu Ala Met Lys Lys Tyr Ser Gln Ile Leu Ser His Phe Glu Lys Leu
          115          120          125
Glu Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu
          130          135          140
Leu Gln Trp Met Glu Glu Thr Glu
145           150

```

&lt;210&gt; 13

&lt;211&gt; 127

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

```

Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala Thr Asn Leu Gln
 1           5           10           15
Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg Gly Ser Val Gln Ala Lys
          20           25           30
Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg Arg Thr Glu Ser Leu Gln
          35           40           45
Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu Leu Arg His Leu Leu Arg
          50           55           60
Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr
65           70           75           80
Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr Ile Lys
          85           90           95
Lys Asp Leu Arg Leu Cys Leu Glu Pro Gln Ala Ala Val Val Lys Ala
          100          105          110
Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met Glu Glu Thr Glu
          115          120          125

```

&lt;210&gt; 14

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

```

Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile
 1           5           10           15

```

&lt;210&gt; 15



<211> 15  
 <212> PRT  
 <213> Homo sapiens

<400> 15  
 Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr Thr  
 1 5 10 15

<210> 16  
 <211> 15  
 <212> PRT  
 <213> Homo sapiens

<400> 16  
 Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys  
 1 5 10 15

<210> 17  
 <211> 15  
 <212> PRT  
 <213> Homo sapiens

<400> 17  
 Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met  
 1 5 10 15

<210> 18  
 <211> 824  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> CDS  
 <222> (71)...(598)

<400> 18  
 tgggagacat cgatagccct gattgatctc tttgaatttt cgcttctggt ctccaggatc 60  
 taggtgtaag atg aaa ggc ttt ggt ctt gcc ttt gga ctg ttc tcc gct 109  
 Met Lys Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala  
 1 5 10  
 gtg ggt ttt ctt ctc tgg act cct tta act ggg ctc aag acc ctc cat 157  
 Val Gly Phe Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His  
 15 20 25  
 ttg gga agc tgt gtg att act gca aac cta cag gca ata caa aag gaa 205  
 Leu Gly Ser Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu  
 30 35 40 45  
 ttt tct gag att cgg gat agt gtg caa gct gaa gat aca aat att gac 253  
 Phe Ser Glu Ile Arg Asp Ser Val Gln Ala Glu Asp Thr Asn Ile Asp  
 50 55 60  
 atc aga att tta agg acg act gag tct ttg aaa gac ata aag tct ttg 301  
 Ile Arg Ile Leu Arg Thr Thr Glu Ser Leu Lys Asp Ile Lys Ser Leu  
 65 70 75

```

gat agg tgc tgc ttc ctt cgt cat cta gtg aga ttc tat ctg gac agg      349
Asp Arg Cys Cys Phe Leu Arg His Leu Val Arg Phe Tyr Leu Asp Arg
      80                      85                      90

gta ttc aaa gtc tac cag acc cct gac cac cat acc ctg aga aag atc      397
Val Phe Lys Val Tyr Gln Thr Pro Asp His His Thr Leu Arg Lys Ile
      95                      100                     105

agc agc ctc gcc aac tcc ttt ctt atc atc aag aag gac ctc tca gtc      445
Ser Ser Leu Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val
     110                      115                      120                     125

tgt cat tct cac atg gca tgt cat tgt ggg gaa gaa gca atg gag aaa      493
Cys His Ser His Met Ala Cys His Cys Gly Glu Glu Ala Met Glu Lys
                   130                      135                      140

tac aac caa att ctg agt cac ttc ata gag ttg gaa ctt cag gca gcg      541
Tyr Asn Gln Ile Leu Ser His Phe Ile Glu Leu Glu Leu Gln Ala Ala
                   145                      150                      155

gtg gta aag gct ttg gga gaa cta ggc att ctt ctg aga tgg atg gag      589
Val Val Lys Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met Glu
                   160                      165                      170

gag atg cta tagatgaaag tggagaggct gctgagaaca ctctgtcca      638
Glu Met Leu
     175

agaatctcag acctcagcac catgaagaca tggccccagg tgctggcatt tctactcaag      698
agttccagtc ctcagcacca cgaagatggc ctcaaaccac cacccttttg tgatataact      758
tagtgctagc tatgtgtata ttatttctac attattggct ccottatgtg aatgccttca      818
tgtgtc      824

```

<210> 19  
 <211> 176  
 <212> PRT  
 <213> Mus musculus

```

<400> 19
Met Lys Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala Val Gly Phe
 1      5      10      15
Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His Leu Gly Ser
 20      25      30
Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe Ser Glu
 35      40      45
Ile Arg Asp Ser Val Gln Ala Glu Asp Thr Asn Ile Asp Ile Arg Ile
 50      55      60
Leu Arg Thr Thr Glu Ser Leu Lys Asp Ile Lys Ser Leu Asp Arg Cys
 65      70      75      80
Cys Phe Leu Arg His Leu Val Arg Phe Tyr Leu Asp Arg Val Phe Lys
 85      90      95
Val Tyr Gln Thr Pro Asp His His Thr Leu Arg Lys Ile Ser Ser Leu
 100     105     110
Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys His Ser
 115     120     125
His Met Ala Cys His Cys Gly Glu Glu Ala Met Glu Lys Tyr Asn Gln
 130     135     140

```

Ile Leu Ser His Phe Ile Glu Leu Glu Leu Gln Ala Ala Val Val Lys  
 145 150 155 160  
 Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met Glu Glu Met Leu  
 165 170 175

<210> 20  
 <211> 152  
 <212> PRT  
 <213> Mus musculus

<400> 20  
 Leu Lys Thr Leu His Leu Gly Ser Cys Val Ile Thr Ala Asn Leu Gln  
 1 5 10 15  
 Ala Ile Gln Lys Glu Phe Ser Glu Ile Arg Asp Ser Val Gln Ala Glu  
 20 25 30  
 Asp Thr Asn Ile Asp Ile Arg Ile Leu Arg Thr Thr Glu Ser Leu Lys  
 35 40 45  
 Asp Ile Lys Ser Leu Asp Arg Cys Cys Phe Leu Arg His Leu Val Arg  
 50 55 60  
 Phe Tyr Leu Asp Arg Val Phe Lys Val Tyr Gln Thr Pro Asp His His  
 65 70 75 80  
 Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Ile Ile Lys  
 85 90 95  
 Lys Asp Leu Ser Val Cys His Ser His Met Ala Cys His Cys Gly Glu  
 100 105 110  
 Glu Ala Met Glu Lys Tyr Asn Gln Ile Leu Ser His Phe Ile Glu Leu  
 115 120 125  
 Glu Leu Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Gly Ile Leu  
 130 135 140  
 Leu Arg Trp Met Glu Glu Met Leu  
 145 150

<210> 21  
 <211> 16  
 <212> PRT  
 <213> Mus musculus

<400> 21  
 Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe Ser Glu Ile Arg  
 1 5 10 15

<210> 22  
 <211> 15  
 <212> PRT  
 <213> Mus musculus

<400> 22  
 Leu Asp Arg Val Phe Lys Val Tyr Gln Thr Pro Asp His His Thr  
 1 5 10 15

<210> 23  
 <211> 15  
 <212> PRT  
 <213> Mus musculus

<400> 23  
 Leu Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys

10

1 5 10 15

<210> 24  
 <211> 15  
 <212> PRT  
 <213> Mus musculus

<400> 24  
 Val Val Lys Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met  
 1 5 10 15

<210> 25  
 <211> 144  
 <212> PRT  
 <213> Mus musculus

<400> 25  
 Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe Ser Glu  
 1 5 10 15  
 Ile Arg Asp Ser Val Gln Ala Glu Asp Thr Asn Ile Asp Ile Arg Ile  
 20 25 30  
 Leu Arg Thr Thr Glu Ser Leu Lys Asp Ile Lys Ser Leu Asp Arg Cys  
 35 40 45  
 Cys Phe Leu Arg His Leu Val Arg Phe Tyr Leu Asp Arg Val Phe Lys  
 50 55 60  
 Val Tyr Gln Thr Pro Asp His His Thr Leu Arg Lys Ile Ser Ser Leu  
 65 70 75 80  
 Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys His Ser  
 85 90 95  
 His Met Ala Cys His Cys Gly Glu Glu Ala Met Glu Lys Tyr Asn Gln  
 100 105 110  
 Ile Leu Ser His Phe Ile Glu Leu Glu Leu Gln Ala Ala Val Val Lys  
 115 120 125  
 Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met Glu Glu Met Leu  
 130 135 140

<210> 26  
 <211> 144  
 <212> PRT  
 <213> Homo sapiens

<400> 26  
 Cys Val Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp  
 1 5 10 15  
 Ile Arg Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile  
 20 25 30  
 Leu Arg Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys  
 35 40 45  
 Cys Leu Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys  
 50 55 60  
 Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu  
 65 70 75 80  
 Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys His Ala  
 85 90 95  
 His Met Thr Cys His Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser Gln  
 100 105 110  
 Ile Leu Ser His Phe Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys

115	120	125
Ala Leu Gly Glu Leu Asp Ile	Leu Leu Gln Trp Met	Glu Glu Thr Glu
130	135	140

<210> 27  
 <211> 38  
 <212> PRT  
 <213> Homo sapiens

<400> 27
Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser Gln Ile Leu Ser His Phe
1 5 10 15
Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu
20 25 30
Asp Ile Leu Leu Gln Trp
35

<210> 28  
 <211> 71  
 <212> PRT  
 <213> Homo sapiens

<400> 28
Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg
1 5 10 15
Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg
20 25 30
Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu
35 40 45
Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr
50 55 60
Gln Thr Pro Asp His Tyr Thr
65 70

<210> 29  
 <211> 92  
 <212> PRT  
 <213> Homo sapiens

<400> 29
Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg
1 5 10 15
Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg
20 25 30
Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu
35 40 45
Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr
50 55 60
Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn
65 70 75 80
Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys
85 90

<210> 30  
 <211> 82  
 <212> PRT  
 <213> Homo sapiens

<400> 30  
 Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu  
 1 5 10 15  
 Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp  
 20 25 30  
 Leu Arg Leu Cys His Ala His Met Thr Cys His Cys Gly Glu Glu Ala  
 35 40 45  
 Met Lys Lys Tyr Ser Gln Ile Leu Ser His Phe Glu Lys Leu Glu Pro  
 50 55 60  
 Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln  
 65 70 75 80  
 Trp Met

<210> 31  
 <211> 36  
 <212> PRT  
 <213> Homo sapiens

<400> 31  
 Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu  
 1 5 10 15  
 Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp  
 20 25 30  
 Leu Arg Leu Cys  
 35

<210> 32  
 <211> 61  
 <212> PRT  
 <213> Homo sapiens

<400> 32  
 Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys His  
 1 5 10 15  
 Ala His Met Thr Cys His Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser  
 20 25 30  
 Gln Ile Leu Ser His Phe Glu Lys Leu Glu Pro Gln Ala Ala Val Val  
 35 40 45  
 Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met  
 50 55 60

<210> 33  
 <211> 756  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> CDS  
 <222> (71)...(532)

<400> 33  
 tgggagacat cgatagccct gattgatctc tttgaatttt cgcttctggt ctccaggatc 60  
 taggtgtaag atg aaa ggc ttt ggt ctt gcc ttt gga ctg ttc tcc gct 109  
 Met Lys Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala  
 1 5 10

gtg ggt ttt ctt ctc tgg act cct tta act ggg ctc aag acc ctc cat 157  
Val Gly Phe Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His  
15 20 25

ttg gga agc tgt gtg att act gca aac cta cag gca ata caa aag gaa 205  
Leu Gly Ser Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu  
30 35 40 45

ttt tct gag att cgg gat agt gtg tct ttg gat agg tgc tgc ttc ctt 253  
Phe Ser Glu Ile Arg Asp Ser Val Ser Leu Asp Arg Cys Cys Phe Leu  
50 55 60

cgt cat cta gtg aga ttc tat ctg gac agg gta ttc aaa gtc tac cag 301  
Arg His Leu Val Arg Phe Tyr Leu Asp Arg Val Phe Lys Val Tyr Gln  
65 70 75

acc cct gac cac cat acc ctg aga aag atc agc agc ctc gcc aac tcc 349  
Thr Pro Asp His His Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser  
80 85 90

ttt ctt atc atc aag aag gac ctc tca gtc tgt cat tct cac atg gca 397  
Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys His Ser His Met Ala  
95 100 105

tgt cat tgt ggg gaa gaa gca atg gag aaa tac aac caa att ctg agt 445  
Cys His Cys Gly Glu Glu Ala Met Glu Lys Tyr Asn Gln Ile Leu Ser  
110 115 120 125

cac ttc ata gag ttg gaa ctt cag gca gcg gtg gta aag gct ttg gga 493  
His Phe Ile Glu Leu Glu Leu Gln Ala Ala Val Val Lys Ala Leu Gly  
130 135 140

gaa cta ggc att ctt ctg aga tgg atg gag gag atg cta tagatgaaag 542  
Glu Leu Gly Ile Leu Leu Arg Trp Met Glu Glu Met Leu  
145 150

tggataggct gctgagaaca ctctgtcca agaattctcag acctcagcac catgaagaca 602  
tggccccagg tgctggcatt tctactcaag agttccagtc ctcagcacca cgaagatggc 662  
ctcaaaccac caccctttg tgatataact tagtgctagc tatgtgtata ttatttctac 722  
attattggct cccttatgtg aatgccttca tgtg 756

&lt;210&gt; 34

&lt;211&gt; 154

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 34

Met Lys Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala Val Gly Phe  
1 5 10 15  
Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His Leu Gly Ser  
20 25 30  
Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe Ser Glu  
35 40 45  
Ile Arg Asp Ser Val Ser Leu Asp Arg Cys Cys Phe Leu Arg His Leu  
50 55 60  
Val Arg Phe Tyr Leu Asp Arg Val Phe Lys Val Tyr Gln Thr Pro Asp

[illegible]

```
<210> 35
<211> 130
<212> PRT
<213> Mus musculus
```

[illegible]

```
<210> 36
<211> 27
<212> DNA
<213> Homo sapiens
```

<400> 36  
agattctatc tggacagggt attcaaa

27

```
<210> 37
<211> 17
<212> DNA
<213> Homo sapiens
```

<400> 37  
gcgaggctga tctttct

17

```
<210> 38
<211> 25
<212> DNA
<213> Mus musculus
```



<400> 38  
tggcgaggct gctgatcttt ctcag 25  
  
<210> 39  
<211> 25  
<212> DNA  
<213> Mus musculus  
  
<400> 39  
ctttatgtct ttcaaagact cagtc 25  
  
<210> 40  
<211> 26  
<212> DNA  
<213> Mus musculus  
  
<400> 40  
catcagaatt ttaaggacga ctgagt 26  
  
<210> 41  
<211> 25  
<212> DNA  
<213> Mus musculus  
  
<400> 41  
ggtggtcagg ggtctggtag acttt 25  
  
<210> 42  
<211> 23  
<212> DNA  
<213> Mus musculus  
  
<400> 42  
ggtgcatatt cctgggtggct aga 23  
  
<210> 43  
<211> 25  
<212> DNA  
<213> Mus musculus  
  
<400> 43  
attgcagtgt aagggaatac agaga 25

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/40309

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : A61K 38/00, 39/00, 45/00

US CL : 424/85.1, 198.1; 514/2

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/85.1, 198.1; 514/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A ✓	WO 99/03982 A1 (HUMAN GENOME SCIENCE, INC.) 28 January 1999 (28.01.1999), see entire document.	1-18
A ✓	US 6,486,301 B1 (EBNER et al) 26 November 2002 (26.11.2002), see entire document.	1-18
A ✓	BLUMBERG et al. Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function. Cell. 12 January 2001, Vol. 104, No. 1, pages 9-19, see entire document.	1-18

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;"

document member of the same patent family

Date of the actual completion of the international search

02 April 2003 (02.04.2003)

Date of mailing of the international search report

22 APR 2003

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Melissa D. Roberts for  
Christopher Yaen

Telephone No. 703-308-0196

**INTERNATIONAL SEARCH REPORT**

PCT/US02/40309

**Continuation of B. FIELDS SEARCHED Item 3:**

STN DATABASE, MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, SCISEARCH, USPATFULL, PCTFULL

**THIS PAGE BLANK (USPTO)**